Lifitegrast

Drug Profile

Lifitegrast

Alternative Names: SAR-1118; SAR-1119; SHP606; SPD606; Xiidra

Latest Information Update: 22 Jul 2017

Price : $50

At a glance

  • Originator Sunesis Pharmaceuticals
  • Developer SARcode Bioscience; Shire
  • Class Eye disorder therapies; Small molecules
  • Mechanism of Action Lymphocyte function-associated antigen-1 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Dry eyes
  • No development reported Allergic conjunctivitis; Atopic dermatitis; Diabetic macular oedema; Ocular inflammation; Psoriasis

Most Recent Events

  • 14 Jun 2017 Efficacay and safety data from pooled analysis in Dry Eyes presented at the 18th Annual Congress of the European League Against Rheumatism (EULAR-2017)
  • 09 May 2017 SARcode and John Hopkins University terminate a phase Ib trial in Diabetic macular oedema in USA due to little or no bioactivity shown in preliminary analysis (NCT00936520)
  • 21 Feb 2017 Shire announces intention to submit MAA to the EMA for Dry eyes disease in 2017 (Shire pipeline, February 2017)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top